Optimal length of triple therapy for<i>H pylori</i>eradication in a population with high prevalence of infection in Chile

Riquelme, Arnoldo; Soza, Alejandro; Pedreros, Cesar; Bustamante, Andrea; Valenzuela, Felipe; Otárola, Francisco Jiménez; Abbott, E. Emily; Arellano, Marco; Medina, Brenda; Pattillo, Alejandro; Greig, Douglas; Arrese, Marco; Rollán, Antonio

doi:10.3748/wjg.v13.i21.2967

Cited by 8 publications

(10 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are similar to those observed in the works of Bellelis [20], and Coelho [22] in research studies also conducted in Brazil. Results in works from Taiwan [23], Kuwait [24], Hong Kong [25], Iran [26], and Chile [27] have presented similar results regarding the efficacy of triple therapy. Metaanalysis of published works regarding the differences between the PPI in H. pylori treatment regimens showed eradication rates between 82% and 84% when they were combined with amoxicillin and clarithromycin [15,16].…”

Section: Discussionmentioning

confidence: 68%

See 1 more Smart Citation

Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients

Felga

Silva

Navarro–Rodriguez

et al. 2010

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: The scheme proton pump inhibitor/amoxicillin/clarithromycin (PPI/AC) is still the first-line treatment for Helicobacter pylori (H. pylori) infections despite evidence suggesting its failure in up to 20% to 30% of patients. Methodology: This study involved 493 patients who were prescribed omeprazole (20 mg twice a day) or another proton pump inhibitor in equivalent dosage, amoxicillin (1 g twice a day), and clarithromycin (500 mg twice a day) for seven days. Efficacy was determined by negative urease test and absence of H. pylori on gastric biopsy samples twelve weeks after the end of treatment. Safety was defined according to the adverse effects reported. Mean age of the patients was (± SD) 48.96 ± 13, and demographic and clinical data were recorded for correlation with treatment outcomes. Results: Out of 493 patients, 316 (64.1%) presented duodenal ulcer, 111 (22.5%) gastric ulcer, and 66 (14.4%) simultaneous gastric and duodenal ulcers. Additionally, 267 (54.2%) patients had at least one risk factor for peptic ulcer disease, smoking being the most common (99 [36.5%]). Successful eradication was achieved in 408 patients. The eradication rates per protocol, and according to the intention to treat, were 88.8% and 82.7%, respectively. Of 164 (35.5%) patients who presented adverse effects, 100 (61%) reported them as mild and only six (3.7%) patients had to discontinue treatment. Previous use of tobacco and non-steroid anti-inflammatory drugs was the only risk factor for treatment failure (P 0.00). Conclusion: PPI/AC is still a valuable and remarkably tolerable option for first-line H. pylori eradication in Brazil.

show abstract

Section: Discussionmentioning

confidence: 68%

“…Due to its safety profile, cost, and efficacy, triple therapy with a PPI, amoxicillin, and clarithromycin was regarded by the first Maastricht Consensus as the first option for eradication, and this position was subsequently endorsed by the following editions of this panel [5,27] as well as by the Brazilian consensus on H. pylori [28].…”

Section: Discussionmentioning

confidence: 99%

Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients

Felga

Silva

Navarro–Rodriguez

et al. 2010

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…Sin embargo, en otros países, como Brasil y Reino Unido, las tasas de erradicación fueron superiores 19,51 , siendo estos resultados similares a los obtenidos en países con bajas tasas de resistencia a claritromicina (menor del 15 al 20%). Adicionalmente, con terapias mayores a 7 días de duración no se encontró mayor eficacia de erradicación, como en los casos de Estados Unidos, Colombia y Chile 24,41,42 . Estos resultados son equivalentes a los observados en el metaanálisis realizado por Fuccio et al 62 , en el cual no se encontró una mayor tasa de erradicación en terapias superiores de 7 días, y de manera similar, en 3 ensayos clínicos aleatorizados conducidos por Kim et al 63 , Zagari et al 64 , donde los regímenes de 2 semanas no fueron superiores a los de una semana.…”

Section: Discussionunclassified

Tratamiento ideal del Helicobacter pylori: una revisión sistemática

Sierra

Forero

Rey

2014

Revista de Gastroenterología de México

View full text Add to dashboard Cite

show abstract

“…It has been recognized as the main bacterial agent of chronic gastritis and duodenal ulcer, affecting more than 50% the world population and almost 70% of the Latin American population (8, 11, 19, 20, 21, 24). …”

Section: Introductionmentioning

confidence: 99%

“…Some patients can develop atrophic chronic gastritis, considered as a risk factor for further occurrence of adenocarcinoma and gastric lymphoma (20, 21). For this reason, H. pylori has been considered as a Group I cancer biological agent (21).…”

Section: Introductionmentioning

confidence: 99%

Isolation of Helicobacter pylori in gastric mucosa and susceptibility to five antimicrobial drugs in Southern Chile

Otth

Wilson

Fernández

et al. 2011

Braz. J. Microbiol.

View full text Add to dashboard Cite

Helicobacter pylori colonizes more than 50% of the world population thus, it is considered an important cause of gastric cancer.The aim of this study was to determine the isolation frequency of H. pylori in Southern Chile from patients with symptomatology compatible with gastritis or gastric ulcer and to correlate these findings with demographic parameters of infected patients and the susceptibility profiles of the isolated strains to the antimicrobial drugs used in the eradication treatments.A total of 240 patients were enrolled in the study. Each gastric biopsy was homogenized and seeded onto blood agar plates containing a selective antibiotics mixture (DENT supplement). Plates were incubated at 37° C in a microaerophilic environment for five days.The susceptibility profiles to amoxicillin, ciprofloxacin, clarithromycin, tetracycline and metronidazole were determined using the E-test method.H. pylori was isolated from 99 patients (41.3%) with slightly higher frequency in female (42% positive cultures) than male (40.2% positive cultures).With regard to age and educational level, the highest isolation frequencies were obtained in patients between 21–30 (55%) and 41–50 (52.6%) years old, and patients with secondary (43.9%) and university (46.2%) educational levels.Nineteen (21.6%) strains showed resistance to at least one antimicrobial drug. Tetracycline was the most active antimicrobial in vitro, whereas metronidazole was the less active. One strain (5.3%) showed resistance to amoxicillin, clarithomycin and metronidazole, simultaneously.

show abstract

Optimal length of triple therapy forH pylorieradication in a population with high prevalence of infection in Chile

Cited by 8 publications

References 42 publications

Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients

Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients

Tratamiento ideal del Helicobacter pylori: una revisión sistemática

Isolation of Helicobacter pylori in gastric mucosa and susceptibility to five antimicrobial drugs in Southern Chile

Contact Info

Product

Resources

About